Indeed, patatin-like phospholipase domain-containing protein 3 (PNPLA3) genetic polymorphisms are associated with increased risk of liver disease progression, cirrhosis, and HCC (48–50), and emerging data suggest that PNPLA3 may play a role in differential response to GLP-1 based regimens in MASH. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.